Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
26/03/2026 11:33
March 26 (Reuters) - Mabpharm Ltd 2181.HK: FY PROFIT AND TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE RMB57.1 MILLION FY REVENUE RMB 646.1 MILLION Further company coverage: 2181.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008